2:
Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2: analysis of the HIV-2 Belgium and Luxembourg database.
Ruelle J, Roman F, Vandenbroucke AT, Lambert C, Fransen K, Echahidi F, Piérard D, Verhofstede C, Van Laethem K, Delforge ML, Vaira D, Schmit JC, Goubau P.
BMC Infect Dis. 2008 Feb 27;8:21.
PMID: 18304321 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
3:
Drug-class-wide resistance to antiretrovirals in HIV-infected patients failing therapy: prevalence, risk factors and virological outcome.
Tozzi V, Zaccarelli M, Bonfigli S, Lorenzini P, Liuzzi G, Trotta MP, Forbici F, Gori C, Bertoli A, Bellagamba R, Narciso P, Perno CF, Antinori A; Collaborative Group for Clinical Use of HIV Genotype Resistance Test.
Antivir Ther. 2006;11(5):553-60.
PMID: 16964822 [PubMed - indexed for MEDLINE]
Related Articles
5:
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 Trial.
Duvivier C, Ghosn J, Assoumou L, Soulié C, Peytavin G, Calvez V, Génin MA, Molina JM, Bouchaud O, Katlama C, Costagliola D; ANRS 121 study group.
J Antimicrob Chemother. 2008 Oct;62(4):797-808. Epub 2008 Jul 18.
PMID: 18641035 [PubMed - indexed for MEDLINE]
Related Articles
8:
The impacts of current antiretroviral therapy regimens on Chinese AIDS patients and their implications for HIV-1 drug resistance mutation.
Zhang M, Han XX, Cui WG, Jia MH, Meng XD, Xing AH, Wu YH, Yang YY, Lu CM, Hu QH, Dai D, Zhang ZN, Shang H.
Jpn J Infect Dis. 2008 Sep;61(5):361-5.
PMID: 18806342 [PubMed - indexed for MEDLINE]
Related Articles
9:
[Prevalence of resistance to antiretroviral drugs in Spain]
Larrú Martínez B, de José MI, Bellón JM, Gurbindo MD, León JA, Ciria L, Ramos JT, Mellado MJ, Pocheville I, Jiménez JL, Muñoz-Fernández MA.
An Pediatr (Barc). 2007 Aug;67(2):104-8. Spanish.
PMID: 17692254 [PubMed - indexed for MEDLINE]
Related Articles
12:
The effect of number of mutations and of drug-class sparing on virological response to salvage genotype-guided antiretroviral therapy.
Ciancio BC, Trotta MP, Lorenzini P, Forbici F, Visco-Comandini U, Gori C, Bonfigli S, Bellocchi MC, Sette P, D'Arrigo R, Tozzi V, Zaccarelli M, Boumis E, Narciso P, Perno CF, Antinori A.
Antivir Ther. 2003 Dec;8(6):611-6.
PMID: 14760895 [PubMed - indexed for MEDLINE]
Related Articles
13:
N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.
Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.
PLoS Med. 2007 Dec;4(12):e335.
PMID: 18052601 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC
14:
HIV-1 residual viremia and proviral DNA in patients with suppressed plasma viral load (<400 HIV-RNA cp/ml) during different antiretroviral regimens.
Nicastri E, Palmisano L, Sarmati L, D'Ettorre G, Parisi S, Andreotti M, Buonomini A, Pirillo FM, Narciso P, Bellagamba R, Vullo V, Montano M, Di Perri G, Andreoni M.
Curr HIV Res. 2008 May;6(3):261-6.
PMID: 18473790 [PubMed - indexed for MEDLINE]
Related Articles
19:
HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance.
Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW.
J Infect Dis. 2005 Aug 1;192(3):456-65. Epub 2005 Jul 5.
PMID: 15995959 [PubMed - indexed for MEDLINE]
Related Articles Free article in PMC